Jun. 2 at 11:55 PM
$DTIL Encouraging, but it is still a small data set. We will have to see if the results are confirmed in a larger trial.
The company plans to raise more funding to support a Phase 2 trial (N=150-200). Depending on feedback from the FDA, that trial could start in the first half of next year. Tune will explore combinations in future trials as well.
At least two other companies, nChroma Bio and Epigenic Therapeutics, are also testing therapies for chronic HBV.
